Michael Chiorazzi, MD, PhD
Assistant Professor of Internal Medicine (Medical Oncology)Cards
About
Research
Publications
2025
Humanization of CD47 enables development of functional human neutrophils via postirradiation remodeling of the bone marrow
Sefik E, Philbrick W, Zhang F, Agrawal K, Van Lee B, Sam J, Karatepe K, Zheng Y, Liang K, Peng S, Mirza H, Rangavajhula A, Simon P, Arun N, Babu P, Eynon E, Chiorazzi M, Shan L, Halene S, Luo H, Rongvaux A, Kluger Y, Flavell R. Humanization of CD47 enables development of functional human neutrophils via postirradiation remodeling of the bone marrow. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2426546122. PMID: 40956886, PMCID: PMC12478129, DOI: 10.1073/pnas.2426546122.Peer-Reviewed Original ResearchConceptsBone marrowHuman CD47Human granulocyte-macrophage progenitorsHuman immune developmentMature human monocytesHuman neutrophilsHumanized mouse modelNeutrophil extracellular trap formationHuman hematopoietic stemGranulocyte-macrophage progenitorsHuman M-CSFHuman immune responseGenetically modified miceResponse to inflammationExtracellular trap formationHuman bone marrowCD47 promoterHuman immune systemPhysiological levelsNK cellsHumanized miceDendritic cellsHematopoietic stemMyeloid lineageHuman hematopoiesisPhase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC).
Bhatia A, Wei W, Chiorazzi M, Deshpande H, Reynolds J, Gehan D, Tara H, Newton B, Verma A, Sayed Z, Roche A, Mehra S, Judson B, Yarbrough W, Burtness B. Phase 2 trial of dual EGFR inhibition with cetuximab and afatinib in patients with recurrent/metastatic head and neck squamous cell cancers (HNSCC). Journal Of Clinical Oncology 2025, 43: 6023-6023. DOI: 10.1200/jco.2025.43.16_suppl.6023.Peer-Reviewed Original ResearchHead and neck squamous cell cancerEpidermal growth factor receptorMedian overall survivalCombination of cetuximabAdverse eventsHuman epidermal growth factor receptor (HER)-2Recurrent/metastatic head and neck squamous cell cancerRefractory to platinum-based chemotherapyEpidermal growth factor receptor targetEpidermal growth factor receptor inhibitionSingle-arm phase II trialPhosphorylated epidermal growth factor receptorCommonest adverse eventsP16+ diseaseProgression-free survivalImmune checkpoint therapyP16-positive tumorsPlatinum-based chemotherapyPrimary tumor locationPhase 2 trialPhase II trialSquamous cell cancerPost-treatment biopsiesTrials of chemotherapyEGFR inhibitor treatmentReal world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era
Lee D, Pan A, Yaskolko M, Chiorazzi M, Bhatia A, Burtness B, Ishizuka J. Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era. Frontiers In Oncology 2025, 15: 1577509. PMID: 40416868, PMCID: PMC12099209, DOI: 10.3389/fonc.2025.1577509.Peer-Reviewed Original ResearchHead and neck squamous cell carcinomaCombined positive scoreAnti-PD1 monotherapyMetastatic head and neck squamous cell carcinomaOral cavity primariesMetastatic head and neck cancerNon-HPV-associated tumorsPatients treated first-lineToxicity of combined treatmentNeck squamous cell carcinomaReal-world treatment patternsHead and neck cancerFlatiron Health databaseAnti-PD1 therapyChemotherapy improves survivalHPV-associated diseasesFirst-line treatmentSquamous cell carcinomaLog-rank testSubgroup of patientsKaplan-Meier curvesTreatment group differencesKEYNOTE-048Non-HPVAnti-PD1Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies
Exposito F, Connolly K, Tang T, Chiorazzi M, Hunt B, Cardenas J, Nguyen D, Joshi N, Politi K. Preclinical Models of Solid Cancers for Testing Cancer Immunotherapies. Annual Review Of Cancer Biology 2025, 9: 285-305. DOI: 10.1146/annurev-cancerbio-062822-024810.Peer-Reviewed Original ResearchResponse to immunotherapyDevelopment of immunotherapyStandard treatment optionCancer immunotherapy drugsCancer-immune interactionsNumerous cancer typesImmunotherapy resistanceImmunotherapy drugsCancer immunologyPreclinical modelsTreatment optionsMouse modelImmunotherapyCancer typesAdvanced in vitro systemsHuman modelTherapyCancerMiceImmunologyDrugEngineering Mice to Study Human Immunity
Sefik E, Xiao T, Chiorazzi M, Odell I, Zhang F, Agrawal K, Micevic G, Flavell R. Engineering Mice to Study Human Immunity. Annual Review Of Immunology 2025, 43: 451-487. PMID: 40020225, DOI: 10.1146/annurev-immunol-082523-124415.Peer-Reviewed Original ResearchHumanized miceHuman hematopoiesisImmune responseImmune systemHumanized mouse modelHuman hematopoietic stemImmunocompromised murine hostsResident immune cellsHuman immune responseStudy human immunityHuman immune systemIntegration of multi-omicsHematopoietic stemImmune cell growthImmune cellsEngineered MiceProgenitor cellsMouse modelImmunological diseasesMurine hostCancer treatmentPreclinical drugsHuman immunityMiceModel disease
2023
Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment
Chiorazzi M, Martinek J, Krasnick B, Zheng Y, Robbins K, Qu R, Kaufmann G, Skidmore Z, Juric M, Henze L, Brösecke F, Adonyi A, Zhao J, Shan L, Sefik E, Mudd J, Bi Y, Goedegebuure S, Griffith M, Griffith O, Oyedeji A, Fertuzinhos S, Garcia-Milian R, Boffa D, Detterbeck F, Dhanasopon A, Blasberg J, Judson B, Gettinger S, Politi K, Kluger Y, Palucka K, Fields R, Flavell R. Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment. Journal For ImmunoTherapy Of Cancer 2023, 11: e006921. PMID: 37487666, PMCID: PMC10373695, DOI: 10.1136/jitc-2023-006921.Peer-Reviewed Original ResearchConceptsHuman tumor microenvironmentTumor microenvironmentTumor-immune interactionsSolid tumorsAdaptive immune activationAdaptive immune populationsIndividual tumor microenvironmentsPatient's hematopoietic systemPatient-derived xenograft tissuesVascular endothelial growth factorBone marrow hematopoietic stemBone marrow aspiratePreclinical drug testingEndothelial growth factorHematopoietic systemAutologous tumorPDX modelingPDX miceImmune activationImmune populationsMarrow aspiratesAutologous systemIndividual patientsLittermate controlsPreclinical predictionsEvaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19
Menez S, Coca S, Moledina D, Wen Y, Chan L, Thiessen-Philbrook H, Obeid W, Garibaldi B, Azeloglu E, Ugwuowo U, Sperati C, Arend L, Rosenberg A, Kaushal M, Jain S, Wilson F, Parikh C, Consortium T, Deng J, Atta M, Bagnasco S, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Evaluation of Plasma Biomarkers to Predict Major Adverse Kidney Events in Hospitalized Patients With COVID-19. American Journal Of Kidney Diseases 2023, 82: 322-332.e1. PMID: 37263570, PMCID: PMC10229201, DOI: 10.1053/j.ajkd.2023.03.010.Peer-Reviewed Original ResearchConceptsSoluble tumor necrosis factor receptor 1Major adverse kidney eventsAdverse kidney eventsAdverse kidney outcomesAcute kidney injuryKidney eventsTumor necrosis factor receptor 1Necrosis factor receptor 1Plasma biomarkersKidney outcomesC-indexFactor receptor 1Hospitalized patientsCOVID-19KDIGO stage 3 acute kidney injuryDialysis-requiring acute kidney injuryStage 3 acute kidney injuryLong-term adverse health outcomesReceptor 1Long-term kidney dysfunctionAvailable blood samplesIdentification of patientsProportional hazards regressionAdverse health outcomesCOVID-19 hospitalization
2022
Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells
Tyagi T, Jain K, Yarovinsky TO, Chiorazzi M, Du J, Castro C, Griffin J, Korde A, Martin KA, Takyar SS, Flavell RA, Patel AA, Hwa J. Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. Journal Of Experimental Medicine 2022, 220: e20212218. PMID: 36305874, PMCID: PMC9814191, DOI: 10.1084/jem.20212218.Peer-Reviewed Original ResearchConceptsCD8 T cellsT cellsTLT-1Non-small cell lung cancer patientsCell lung cancer patientsTREM-like transcript-1Tumor immunosuppressive mechanismsT cell suppressionLung cancer patientsPatient T cellsNF-κB pathwayPatient-derived tumorsDistinct activation phenotypesNSCLC patientsImmunosuppressive mechanismsSyngeneic tumorsHumanized miceImmunoregulatory rolePrognostic significanceImmunocompetent miceCancer patientsCell suppressionActivation phenotypeReduced tumorTumor growthTranscriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function
Martinek J, Lin J, Kim KI, Wang VG, Wu TC, Chiorazzi M, Boruchov H, Gulati A, Seeniraj S, Sun L, Marches F, Robson P, Rongvaux A, Flavell RA, George J, Chuang JH, Banchereau J, Palucka K. Transcriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function. Cell Reports Medicine 2022, 3: 100621. PMID: 35584631, PMCID: PMC9133468, DOI: 10.1016/j.xcrm.2022.100621.Peer-Reviewed Original ResearchConceptsMonocytes/macrophagesDendritic cellsMetastatic melanomaMelanoma cellsMetastatic cutaneous melanomaRegulation of toleranceSpecific transcriptional signatureTranscriptional profilingGene setsLaser capture microdissectionCell-based therapiesTranscriptional signatureCutaneous melanomaDC functionPatient outcomesMetastatic cancerTumor nestsTCGA cohortImmune functionCandidate biomarkersCD14Stromal macrophagesTumor siteTherapeutic opportunitiesAntigen capture
2021
Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19
Menez S, Moledina DG, Thiessen-Philbrook H, Wilson FP, Obeid W, Simonov M, Yamamoto Y, Corona-Villalobos CP, Chang C, Garibaldi BT, Clarke W, Farhadian S, Dela Cruz C, Coca SG, Parikh CR, Investigators T, Ko A, Iwasaki A, Farhadian S, Nelson A, Casanovas-Massana A, White E, Schulz W, Coppi A, Young P, Nunez A, Shepard D, Matos I, Strong Y, Anastasio K, Brower K, Kuang M, Chiorazzi M, Bermejo S, Vijayakumar P, Geng B, Fournier J, Minasyan M, Muenker M, Moore A, Nadkarni G. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19. American Journal Of Kidney Diseases 2021, 79: 257-267.e1. PMID: 34710516, PMCID: PMC8542781, DOI: 10.1053/j.ajkd.2021.09.008.Peer-Reviewed Original ResearchConceptsAdverse kidney outcomesNeutrophil Gelatinase-Associated LipocalinUrinary biomarkersBiomarker levelsKidney outcomesPrimary outcomeClinical AKIKidney injuryComposite outcomeCOVID-19KDIGO stage 3 AKIKidney injury molecule-1Cox proportional hazards regressionEpidermal growth factor levelsStage 3 AKIPrimary composite outcomeInjury molecule-1Kidney disease progressionGelatinase-Associated LipocalinAdditional prognostic informationComposite outcome eventsProportional hazards regressionCOVID-19 patientsGrowth factor levelsCoronavirus disease 2019
Clinical Care
Overview
Michael Chiorazzi, MD, PhD, is a medical oncologist who specializes in the treatment of head and neck cancers. He diagnoses and manages these complex conditions with a variety of individually tailored treatments.
As an assistant professor of internal medicine at Yale School of Medicine, Dr. Chiorazzi conducts research to improve cancer treatment, focusing particularly on the immunological aspects of cancer.
Dr. Chiorazzi received his medical degree from Cornell University Medical College and his doctoral degree from Rockefeller University. He completed a residency in internal medicine and a fellowship in hematology and medical oncology at Yale School of Medicine.
Clinical Specialties
Medical Oncology; Head & Neck Cancers
News
News
- April 23, 2026
New Research Presented from Yale Cancer Center at the AACR Annual Meeting
- April 12, 2024
Yale Cancer Center Faculty and Trainees Present at AACR Annual Meeting
- August 03, 2023Source: Yale News
Method Allows New Insights Into Interplay Between Immune System and Tumors
- April 10, 2023
Yale Cancer Center Experts to Present New Research at Annual AACR Meeting
Get In Touch
Contacts
Administrative Support
Locations
The Anlyan Center
Lab
300 Cedar Street, Fl 5th Floor, Rm S560
New Haven, CT 06519
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.